Sten Madsbad

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander, Sten Madsbad, Jan Lysgaard Madsen et al. · The Lancet · 2002 · 1.3K citations

Medicine, Endocrinology, Internal Medicine +16

Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy

Anthony Barnett, Stephen C. Bain, Paul Bouter et al. · New England Journal of Medicine · 2004 · 916 citations · Full text

Medicine, Nephrology, Pharmacology +12

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll, Thure Krarup, Carolyn F. Deacon et al. · Diabetes · 2001 · 884 citations · Full text

Medicine, Endocrinology, Nutrition +16

Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients

M. Toft-Nielsen, Mette Brimnes Damholt, Sten Madsbad et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 840 citations

Medicine, Endocrinology, Physiology +15

The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion

Lise Kjems, Jens J. Holst, Aage Vølund et al. · Diabetes · 2003 · 580 citations · Full text

Medicine, Endocrinology, Pharmacology +17